Loading clinical trials...
Loading clinical trials...
A Phase 1 Study of the Safety and Efficacy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Malignancies
Conditions
Interventions
CRX100 suspension for infusion
Fludarabine
+1 more
Locations
3
United States
HonorHealth Research Institute
Scottsdale, Arizona, United States
UC San Diego Moores Cancer Center
La Jolla, California, United States
Stanford University
Stanford, California, United States
Start Date
January 8, 2021
Primary Completion Date
August 1, 2025
Completion Date
October 1, 2026
Last Updated
February 8, 2024
NCT07446322
NCT07541924
NCT07536113
NCT06681064
NCT04693377
NCT07529301
Lead Sponsor
BioEclipse Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions